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Abstract: Testicular germ cell tumors (TGCTs) are the commonest tumors in young men. With the advancement of 
chemotherapies, most TGCTs are successfully cured, even when diagnosed at an advanced and metastatic stage. 
However, a proportion of often young patients, median age 35-40, with advanced disease are not cured and will 
inevitably die. Therefore, there is an unmet need in this small population of young patients who are candidates for 
experimental approaches. We investigated a new therapeutic option for this group of patients, aiming to significantly 
improve their outcome. In recent years, many targeted therapies have been developed which demonstrated high ef-
ficacy and low toxicity. Brentuximab vedotin, a monomethyl auristatin E conjugated CD30 antibody, targets CD30 to 
kill cancer cells. As a large proportion of TGCTs express CD30, in particular embryonal carcinomas, we investigated 
in vitro the efficacy of brentuximab vedotin in treating TGCTs as a single therapy and in combination with commonly 
used chemotherapy drugs. We determined CD30 expression levels in 12 TGCT cell lines, including three cisplatin 
resistant sublines. In general, the efficiency of cancer cell inhibition by brentuximab vedotin correlates with CD30 
expression, but there were some exceptions. We also determined the efficacy of brentuximab vedotin in combina-
tion with commonly used chemotherapy drugs and found synergistic/additive effects with etoposide, paclitaxel and 
SN-38. However, cisplatin, the most commonly used chemotherapy drug in TGCT treatment, exhibited antagonism 
and we showed that cisplatin selectively kills CD30 positive cells. We also found that certain agents, which have 
been reported to induce CD30 expression in other human malignant diseases, including DNA demethylation drugs, 
methotrexate and CD30 ligands, were unable to enhance CD30 expression or brentuximab vedotin efficacy in TGCT 
cells. This study will help to design clinical trials using brentuximab vedotin for the treatment of TGCTs, either as a 
single agent or in combination with current clinical therapies.
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Introduction
Testicular germ cell tumors (TGCTs) are the co- 
mmonest tumors in young men. There are two 
broad types of TGCTs, seminoma and non-sem-
inoma. In the current management of locally 
advanced and metastatic cases, chemothera-
py has a central role. The use of cisplatin, most 
commonly with etoposide and either bleomycin 
or ifosfamide, cures the majority of patients. 
Those with very high levels of tumor markers or 
with liver, brain or bone metastases are less 
likely to be cured. Patients whose tumors are 
refractory to primary therapy have a cure rate 
between 25-50%. This is normally achieved by 
further chemotherapy using cisplatin, or high 
dose of carboplatin based chemotherapy in 
combination with surgery. Less fit patients are 
much less likely to be cured by these approa- 
ches. In addition, following the failure of an ini-
tial salvage therapy, the cure rate is under 25% 
[1-4]. These TGCT patients are often young 
(median age 35-40), thus novel therapeutic 
approaches need to be developed urgently.
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Monoclonal antibody therapy directed against 
unique antigens expressed on cancer cells has 
been successfully applied in many cancer tre- 
atments and antibody-drug conjugates (ADC) 
have extended this technology, allowing deliv-
ery of high doses of cytotoxic drugs to cancer 
cells while largely sparing normal tissues [5]. 
Brentuximab vedotin (Adcetris) is a CD30-di- 
rected monoclonal antibody conjugated to the 
potent inhibitor of microtubule polymerization, 
monomethyl auristatin E. It not only selectively 
targets and kills CD30-expressing cancer cells, 
but also kills surrounding CD30 negative can-
cer cells through a bystander effect [6-8]. Pr- 
eclinical study of brentuximab vedotin in Ho- 
dgkin lymphoma and anaplastic large cell lym-
phoma showed excellent therapeutic effect 
[5]. Following further clinical trials, brentuxim- 
ab vedotin has proven to be a highly promising 
drug for patients with CD30-positive lympho-
mas with limited side-effects. It has been ap- 
proved for the treatment of advanced Hodgkin 
lymphoma and anaplastic large cell lymphoma 
[5]. 
CD30 is expressed by most embryonal carcino-
mas and yolk sac tumors, the aggressive forms 
of non-seminomous TGCTs [9-15]. In semino-
mas, previous reports vary and generally ar- 
ound 10-20% of them were positive [9, 10, 12, 
13, 16]. Our and other’s previous studies in 
clinical samples have shown that chemothera-
py can change CD30 expression from positive 
to negative in more than half of the embryonal 
carcinoma cases [11, 15]. It has been reported 
that TGCTs with retained CD30 expression after 
intensive treatment were associated with a sig-
nificantly poorer prognosis [14], which suggests 
that CD30 is a valid treatment target. Two re- 
cent clinical studies, each with a few patients, 
have demonstrated the potential benefit of 
treating cisplatin-resistant GCTs with brentux-
imab [17, 18]. As CD30 expression in TGCTs 
decreases following chemotherapy, it is possi-
ble that brentuximab vedotin may be more effi-
cient in treating TGCT if used before chemo-
therapy with certain drugs. 
Since TGCTs are commonly treated with plati-
num based regimens, in this study we investi-
gated, using in vitro testicular embryonal carci-
nomas cell line models, the influence of cispla-
tin on CD30 expression levels and the sensi- 
tivity to brentuximab vedotin. As there is limited 
data on the combination of brentuximab vedo-
tin with chemotherapy drugs, we also deter-
mined which chemotherapy drugs commonly 
used for TGCT treatment may have synergistic 
or additive therapeutic effect with brentuximab 
vedotin. CD30 expression in a large number 
of post-radiotherapy non-seminomatous TGCT 
cases were also investigated.
Materials and methods
Patient tissue samples
Post-radiotherapy TGCT tissue blocks (1969-
1983) were retrieved from St Bartholomew’s 
Hospital, Barts Health NHS, London, UK, and 
reviewed (DB) for remaining TGCT lesions to 
construct tissue microarrays as previously de- 
scribed [19]. 91 cases were included in this 
study and the use of patient samples was 
approved by the National Research Ethics 
Service committee, London City & East with a 
Research Ethics Committee reference of 09/
H0704.
Cell lines
Non-seminomatous TGCT cell lines 833K pa- 
rental cisplatin sensitive, 833K cisplatin resis-
tant subline (833KR), Susa parental cisplatin 
sensitive, Susa cisplatin resistant subline (Su- 
saR), GCT27 parental cisplatin sensitive, GCT27 
cisplatin resistant subline (GCT27R), GCT44, 
TERA-1, NTERA-2, NCG2102 and 577MF and a 
seminoma cell line TCam-2 were used. The cis-
platin resistant lines were established by the 
repeated passaging of cells through media con-
taining low doses of cisplatin [20]. The prostate 
cancer cell lines PC3, 22Rv1, DU145, LNCaP 
and osteosarcoma cell line MG63 were also 
used. Cells were maintained in Dulbecco’s Mo- 
dified Eagle Medium (Gibco) supplemented wi- 
th 10% fetal bovine serum (Gibco) and 1% pe- 
nicillin/streptomycin in a controlled atmosp- 
here with 5% CO2 at 37°C, except for TCam- 
2 cells which was maintained in RPMI 1640 
(Gibco) instead of Dulbecco’s Modified Eagle 
Medium.
Drugs used for TGCT treatment
Brentuximab vedotin was kindly provided by 
MILLENNIUM PHARMACEUTICALS, INC free of 
charge through a research collaboration agree-
ment. The chemotherapy drugs used are cispla-
tin (TEVA UK Ltd), methotrexate (Sigma), etopo-
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side (Sigma), SN-38 (Sigma), paclitaxel (Sigma) 
and actinomycin-D (Sigma). 
Cell treatment with intention to manipulate the 
expression of CD30
Gene knockdown by siRNA was performed as 
previously described [21] using the CD30 si- 
RNA from Dharmacon. CD30 Ligand/TNFSF8 
(R&D systems) at a concentration of 50 ng/ml 
was cross-linked using 5 μg/ml His Tag mo- 
noclonal mouse antibody Clone AD1.1.10 (R&D 
systems, MAB0500) before being used for cell 
treatment. Cells were also treated with cisplat-
in at IC50 concentrations of relevant cell lines 
(1.5 μM for 833K and 2.5 uM for GCT27), 10 
μM methotrexate and DNA demethylation ag- 
ents 5-Aza-2’-deoxycytidine (Sigma) at the con-
centration of 5 μm and cladribine (Sigma) at the 
concentration of 3.5 μM for 72 hours to deter-
mine CD30 expression changes. All these ex- 
periments were done in six well cell culture 
plates.
Assessment of cell response to drugs 
Cell response to drugs was assessed by mea-
suring cell viability using the CellTiter 96® 
AQueous assay (Promega) as previously des- 
cribed [21, 22]. Briefly, cells were seeded in 
96-well plates and after 24 hours cells were 
treated with serial dilutions of drug dosages. 
Cell viability was assessed after 72 hours of 
treatment and dose response curves were gen-
erated based on relative cell viability normal-
ized to untreated controls. 
Quantitation of synergism and antagonism in 
drug combinations 
Combined drug treatment were performed as 
previously described [22] with different combi-
nations of IC30 and IC50 between two drugs. 
Killing effect values were used to examine syn-
ergism and antagonism of drugs using Com- 
puSyn software (http://www.combosyn.com/
register.html). Combination index (CI) > 1 indi-
cates antagonistic effect, CI = 1 indicates addi-
tive effect and CI < 1 indicates synergism [23]. 
Western blot analysis
Western blotting was performed as previously 
described [24] using rabbit monoclonal anti-
CD30 EPR4102 (Abcam ab134080), and anti-
β-actin (A5441, Sigma) antibodies. Briefly, cells 
were lysed in RIPA buffer and protein concen-
tration was determined by Bradford assay. Pro- 
teins were mixed with NuPAGE® LDS Sample 
Buffer (BioRad) and reducing agent (BioRad) 
and denatured at 90°C for 5 min. Protein sam-
ples were loaded on 10% polyacrylamide gels 
and transferred onto PVDF membranes (Mil- 
lipore, UK) after separation. Membranes were 
blocked with 5% skimmed powder milk in Tris 
Buffer Saline/0.1% Tween-20 and incubated 
overnight with primary antibodies, followed by 
secondary peroxidase conjugated antibodies 
(Fisher Scientific) for 1 hour at room tempera-
ture. Protein detection was performed with 
Immobilon Western Chemiluminescent HRP 
Substrate (Millipore). β-actin was used as load-
ing control. Relative expression of CD30 was 
quantified in ImageJ.
Immunocytochemistry analysis
Cells were cultured on glass cover slips and 
then fixed with 10% formalin for 20 minutes, 
followed by PBS wash and permeabilization in 
0.5% Tween 20 in PBS. Primary rabbit monoclo-
nal anti-CD30 antibody diluted 1:2000 in PBS 
with 1% BSA was applied for 1 hour at room 
temperature. Primary antibody was omitted 
and only 1% BSA in PBS diluent was used for 
negative control. After wash with 1% Tween 20 
in PBS (PBST), secondary biotinylated anti- 
body from the Vectastain Universal Elite ABC 
kit (Vector Lab) was applied for 30 minutes. The 
cover slips were then washed with PBST and 
incubated with the avidin-peroxidase complex 
from the Vectastain Universal Elite ABC kit for 
20 minutes. Following further PBST wash, the 
cells were incubated with 3,3’-Diaminobenzidine 
solution (BioGenex) for 10 minutes and then 
counterstained with haematoxylin for 3 minut- 
es. After dehydration through 70%, 90% and 
100% ethanol, the cover slips were cleared in 
xylene and mounted on glass slides with mount-
ing medium (DPX, Sigma). 
Immunohistochemistry analysis
Immunohistochemistry analysis was performed 
as previously described [25, 26] using the diag-
nostic CD30 mouse monoclonal antibody clone 
H2 (Dako, M0751) at 1:40 dilution and Vecta- 
stain Universal Elite ABC kit (Vector Lab). CD30 
cytoplasmic expression was scored as nega- 
tive (0), weak (1+), medium (2+) and strong (3+) 
staining.
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Statistics
Dose-response curves for each cytotoxic drug 
were generated within GraphPad (Non-linear 
regression, dose-response inhibition, log (inhib-
itor) vs. response variable slope (4 parameters), 
ordinary fit). IC30 and IC50 were calculated by 
using GraphPad QuickCalcs (http://www.graph-
pad.com/quickcalcs/Ecanything1/) from the 
dose-response curves. Two tailed Fisher’s ex- 
act test was applied to category data. P < 0.05 
was considered as significant.
Results
Determination of CD30 expression in a panel 
of TGCT cell lines 
To analyze CD30 expression levels in both TG- 
CT tissues and cell lines, we first confirmed by 
Western blot the specificity of the rabbit anti-
CD30 antibody using siRNA knockdown of 
CD30 in 833K cells. Two bands around 100 
and 140 KDa were detected and both corre-
sponded to CD30, as they decreased after 
CD30 knockdown by siRNA (Figure 1). These 
detected bands are consistent with the previ-
ously observed sizes of cellular CD30 by We- 
stern blotting [27]. We then checked CD30 
expression levels in 12 TGCT cell lines, includ-
ing three cisplatin resistance sublines, by We- 
stern blotting and immunocytochemistry. The 
two detection methods generated consistent 
CD30 expression results in these cell lines. As 
expected, the teratoma cell line 577MF was 
CD30 negative and the seminoma cell line 
TCam-2 had very low CD30 expression. How- 
ever, among embryonal carcinoma cell lines, 
CD30 expression varied dramatically from st- 
rong expression in 833K cells to very weak 
expression in TERA1 cells. The Yolk Sac carci-
noma cell line GCT44 was also negative (Figure 
2). Interestingly, the cisplatin resistant sublin- 
es 833KR, SusaR and GCT27R all expressed 
much lower levels of CD30 than their parental 
cells and SusaR cells were CD30 negative 
(Figure 2B and 2C).
Cell killing efficacy of brentuximab vedotin in 
correlation with CD30 expression 
Dose-response curves for brentuximab vedotin 
were generated in all 12 TGCT cell lines by MTS 
assay (Figure 3A and 3B). The sensitivity to 
brentuximab vedotin generally correlated to the 
CD30 expression in the cell lines. 833K cells, 
which expressed a high level of CD30, were 
most sensitive (> 500 folds than others) to 
brentuximab vedotin. However, NCG2012 ce- 
lls, which expressed considerable amounts of 
CD30, as detected both by Western blot and 
immunocytochemistry analyses, did not res- 
pond to brentuximab vedotin until the concen-
tration reached over 5000 ng/ml, which was 
potentially due to unspecific toxicity at very hi- 
gh drug doses. TCam-2, which expressed CD30 
Figure 1. CD30 detection by Western blotting. CD30 antibody specificity test using CD30 knockdown by siRNA in 
833K cells (72 hours). Two bands were detected and both correspond to CD30 as they decrease after the knock-
down. A representative Western blotting image was shown with quantification of CD30 expression (the high and low 
molecular weight bands were quantified separately and normalized to the untreated control) presented in bar chart. 
C: untreated control; NT: Non-targeting control; siCD30: CD30 siRNA treated cells.
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in a small proportion of cells, was another cell 
line that did not respond to brentuximab vedo-
tin until at > 5000 ng/ml in concentration. The 
two CD30 negative cell lines, 577MF and 
GCT44, started to respond to brentuximab 
vedotin at > 1000 ng/mg, similar to TERA1, 
which has very low level of CD30 expression. 
While most cell lines, whether they responded 
to brentuximab vedotin at low doses or not, are 
nearly completely killed at 125000 ng/ml con-
centration in three days, around 20% GCT27 
and TCAM2 cells survived at such a high dose 
of brentuximab vedotin. 
The influence of cisplatin treatment on the 
sensitivity of TGCT cells to brentuximab vedo-
tin 
Comparing the 833K, Susa and GCT27 paren-
tal cells with the cisplatin resistant sublines, 
each of the cisplatin resistant cell sublines sh- 
owed more resistance to brentuximab vedotin 
Figure 2. CD30 expression in TGCT cell lines. A. CD30 expression in TGCT cell lines determined by Western blot-
ting with quantification of CD30 expression (both bands normalized to NCG2101) presented in bar chart. B. CD30 
expression in the three pairs of cisplatin sensitive parental TGCT cell lines and resistant sublines (SusaR, GCT27R 
and 833KR) determined by Western blotting with quantification of CD30 expression (both bands normalized to the 
corresponding cisplatin-sensitive parental cell lines) presented in bar chart. C. Representative images of CD30 ex-
pression in these TGCT cell lines determined by immunocytochemistry (400× magnification).
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than its parental line with significantly increas- 
ed IC50 doses for all the sublines (Figure 3B 
and 3C). SusaR and GCT27R cells only start- 
ed to respond to brentuximab vedotin at 1000 
ng/ml, while the parental cell lines started to 
respond at < 10 ng/ml. This brentuximab vedo-
tin sensitivity correlated to the reduced CD30 
expression levels in the resistant sublines 
compared to their parental cells. We further 
investigated the effects of cisplatin treatment 
on CD30 expression levels in 833K, Susa and 
GCT27 cells and observed a significant (P < 
0.01 for all cell lines) reduction in CD30 expres-
sion after treatment as detected by Western 
blotting (Figure 4A) and immunocytochemistry 
analysis (Figure 4B). We then tested the com-
bined treatment of brentuximab vedotin and 
cisplatin for 833K, Susa and GCT27 cells using 
both IC30 and IC50 of cisplatin and brentuxi-
mab vedotin in different dose combinations. An 
antagonistic effect was detected in all three 
cell lines (Figure 4C). 
CD30 expression stimulation in TGCT cells 
As CD30 expression is low or negative in some 
cell lines and post-chemotherapy TGCT embry-
onal carcinoma clinical samples, we attempt- 
ed to induce CD30 in TGCT cells by different 
methods. Firstly, we treated GCT27 and TERA1 
cells with the DNA demethylation agents Cla- 
dribine and 5-Aza-2’-deoxycytidine. To our sur-
prise, both agents decreased instead of in- 
creasing CD30 expression, as determined by 
Western blot (Figure 5A). We then tested the 
effect of CD30 ligand and methotrexate treat-
ments for their potential in stimulating CD30 
expression in TGCT cells using 833K and GC- 
T27 cell lines. Both drug treatment increas- 
ed CD30 expression in 833K cells, but reduced 
CD30 expression in GCT27 cells (Figure 5B). 
Determination of the efficacy of combination 
treatment of brentuximab vedotin with chemo-
therapies 
Based on the above data, the combination 
treatment of brentuximab vedotin with other 
chemotherapy drugs used in the clinic for TGCT 
treatment, including methotrexate, etoposide, 
paclitaxel, SN-38 and actinomycin-D, were test-
ed in 833K, Susa and GCT27 cell lines to de- 
termine which drugs have a similar antagonistic 
effect to brentuximab vedotin as cisplatin and, 
Figure 3. Brentuximab vedotin dose-response 
curves of TGCT cell lines. A. Dose-response 
curves and calculated IC30/IC50 of the six un-
paired TGCT cell lines. B. Dose-response curves 
and calculated IC30/IC50 of the six paired cis-
platin sensitive and resistant TGCT cell lines. C. 
IC50 concentration of BV in six paired TGCT cell 
line. Error bars show ± standard deviation. BV: 
Brentuximab vedotin. ***P < 0.001, **P < 0.01.
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Figure 4. The effect of cisplatin on CD30 expression and brentuximab vedotin sensitivity of TGCT cells. A. Representative Western blotting images and the quan-
tifications of CD30 normalized to the untreated control cells show the reduction of CD30 expression in TGCT cells after cisplatin treatment. B. Representative im-
munocytochemistry images of the reduction of CD30 expression in TGCT cells after cisplatin treatment. C. Antagonism of cisplatin and Brentuximab vedotin in the 
treatment of CD30 positive TGCT cells with cell viability bar chart on the top panel and combination index plot in the bottom panel. C: untreated control; Cis: cisplatin 
treated cells; BV: Brentuximab vedotin; CI: combination index; Fa: Fraction affected.
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more importantly, which drugs have synergistic 
or additive effects to brentuximab vedotin. In 
order to select the dose for the combined tre- 
atment, we firstly generated the dose-response 
curves for each of these drugs in 833K, Susa 
and GCT27 cell lines (Figure 6). Interestingly, 
we observed a unique dose-response effect 
for methotrexate, different from all the other 
drugs. Methotrexate did not affect the prolife- 
ration of cancer cells until reaching certain 
concentrations, after which a small increase in 
methotrexate dose dramatically inhibited can-
cer cell growth and further increases in the 
dose had no additional effect (Figure 6). Con- 
sequently, all three cell lines were not affected 
by 10 nM methotrexate but were maximally 
inhibited at a 100 nM dose. To determine if th- 
is dose response pattern of methotrexate is 
universal for any cancer type, we investigated 
four prostate cancer cell lines PC3, LNCaP, 
22RV1 and DU145 and an osteosarcoma cell 
line MG63 for their methotrexate dose respons-
es. All these cell lines also showed plateauing 
of methotrexate inhibiting effects from certain 
drug concentrations, ranging from 50-500 nM 
in different cell lines. More than 20% of cells 
survived drug concentration > 100-fold of the 
minimum plateauing dose. However, the mini-
mum plateauing doses for these cells were 
reached gradually with increasing methotrex-
ate doses in a range of 10-fold difference (Fi- 
gure 7). 
Once IC30 and IC50 were calculated for all 
drugs, combination treatments with brentuxi-
mab vedotin were performed using both IC30 
and IC50 for different dose combinations. Cell 
viability (%), killing effect (from 0 to 1) and syn-
ergy for methotrexate, etoposide, paclitaxel, 
SN-38 and actinomycin-D are shown in Figures 
8-10. Based on the synergy analysis using 
CompuSyn software, brentuximab vedotin sh- 
owed antagonism with all the tested cytotoxic 
drugs in GCT27 cells and with methotrexate in 
all cell lines. Weak antagonistic effects were 
also detected for etoposide in 833K cells and 
for actinomycin-D in Susa cells. Weak synergy 
with paclitaxel in 833K and Susa cells and with 
etoposide in Susa cells were observed. Additive 
effects were observed for SN-38 in 833K and 
Susa cells and actinomycin-D in 833K cells 
(Figures 8-10).
Figure 5. The impact of previously reported CD30 reactivation agents on CD30 expression in TGCT cells. A. Western 
blotting images of CD30 expression in TGCT cells treated using DNA demethylation agents 5-Aza-2’-deoxycytidine 
and cladribine with the quantification of CD30 expression (both bands normalized to untreated control cells) pre-
sented in bar chart. B. Western blotting images of CD30 expression in TGCT cells treated using methotrexate and 
CD30 Ligand. In 833K cells, the Western blotting was run together with the CD30 knockdown experiment by siRNA 
as presented in Figure 1. The high and low molecular weight bands of CD30 were quantified separately in 833K 
and normalized to untreated control cells. In GCT27, the quantification of both bands of CD30 was normalized to 
the control cells. C: untreated control. AZA: 5-Aza-2’-deoxycytidine treated cells; Cladr: cladribine treated cells; MTX: 
methotrexate treated cells; CD30 L: CD30 Ligand treated cells. 
Brentuximab in testicular germ cell tumor treatment 
863 Am J Cancer Res 2019;9(5):855-871
Figure 7. MTX dose-response in prostate cancer and 
the MG63 osteosarcoma cell lines and the calculat-
ed IC30/IC50.
Determination of the CD30 expression in post-
radiotherapy TGCT lesions 
We performed immunohistochemistry analysis 
to detect CD30 expression in a large cohort of 
post-radiotherapy clinical TGCT samples made 
into TMAs, including 57 non-seminomous TG- 
CTs with pure or areas of embryonal carcinoma 
and 34 mixed seminoma and seminomous TG- 
CTs with embryonal carcinoma components, 
one pure teratoma, three cases of choriocarci-
noma mixed with seminoma and three cases 
of teratoma mixed with seminoma. In 91% 
(52/57) of non-seminomous TGCTs with em- 
bryonal carcinoma components, CD30 expres-
sion was found in > 10% of tumor cells. In 94% 
(32/34) of mixed seminoma and embryonal 
carcinoma/teratoma TGCT cases, CD30 expre- 
ssion was found in > 10% of tumor cells. The 
former type of TGCTs had the trend to express 
CD30 stronger than the mixed tumors (more 
2+/3+ cases, P = 0.096) (Table 1; Figure 11). 
The pure teratoma was CD30 positive, two of 
the three choriocarcinomas were CD30 posi-
tive and the three teratomas mixed with semi-
noma cases were all CD30 negative.
Discussion
Brentuximab vedotin has been approved by 
FDA for the treatment of CD30 positive Hodg- 
kin lymphoma and anaplastic large cell lympho-
ma [5] with a good tolerability and safety pro-
file. Most TGCTs express CD30, in particular 
embryonal carcinomas [9-15]. Therefore, CD30 
positive TGCTs could benefit from brentuximab 
vedotin therapy. Two clinical studies have dem-
onstrated in limited number of patients the po- 
tential benefit of this treatment in post-chemo-
therapy relapsed TGCTs. However, only a small 
proportion of patients responded [17, 18]. Fur- 
ther investigations are required to improve the 
efficacy of brentuximab vedotin in TGCT treat-
ment. Therefore, we determined the prevalence 
of CD30 expression in a considerable large 
panel of TGCT cell lines to establish the sensi-
tivity of TGCT cells to brentuximab vedotin, in 
correlation to CD30 expression levels. We also 
explored the combined treatment of brentux-
Figure 6. Dose-response curves 
for five TGCT chemotherapy drugs 
in three TGCT cell lines 833K, 
Susa and GCT27. (A) Methotrex-
ate; (B) Etoposide; (C) Paclitaxel; 
(D) SN-38 and (E) Actinomycin-D.
Brentuximab in testicular germ cell tumor treatment 
864 Am J Cancer Res 2019;9(5):855-871
Figure 8. The efficacy of brentuximab vedotin in combination with other TGCT chemotherapy drugs in 833K cells. 
Brentuximab vedotin was combined with methotrexate, etoposide, paclitaxel, SN-38 and actinomycin-D for the treat-
ment of 833K cells with the cell viability bar chart showing on the top of the combination index plot for each treat-
ment. The antagonistic effect of brentuximab vedotin IC30 and methotrexate IC30 combination is out of range, so 
that there are only three data points shown in the combination index plot for brentuximab vedotin and methotrexate. 
MTX: methotrexate; BV: brentuximab vedotin; Eto: etoposide; Pac: paclitaxel; ActD: actinomycin-D; CI: combination 
index; Fa: Fraction affected.
imab vedotin with currently used clinical che-
motherapy drugs for TGCT treatment to estab-
lish the best combination to maximally kill 
CD30 positive TGCTs.
We have shown that in the only existing semi-
noma cell line TCAM2, CD30 is only expressed 
in a small proportion of cells, and is not ex- 
pressed in the Yolk Sac carcinoma cell line 
GCT44, which is consistent with previous stu- 
dies [8, 28]. In a panel of embryonal carcinoma 
TGCT cell lines, we detected a wide range of 
CD30 expression levels, which provides good 
in vitro models to study the sensitivity to bren-
tuximab vedotin with respect to CD30 levels 
and to investigate potential mechanisms of 
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Figure 9. The efficacy of Brentuximab vedotin in combination with other TGCT chemotherapy drugs in Susa cells. 
Brentuximab vedotin was combined with methotrexate, etoposide, paclitaxel, SN-38 and actinomycin-D for the 
treatment of Susa cells with the cell viability bar chart showing on the top of the combination index plot for each 
treatment. The antagonistic effect of brentuximab vedotin IC50 and methotrexate IC50 combination is out of range, 
so that there are only three data points shown in the combination index plot for brentuximab vedotin and methotrex-
ate. MTX: methotrexate; BV: brentuximab vedotin; Eto: etoposide; Pac: paclitaxel; ActD: actinomycin-D; CI: combina-
tion index; Fa: Fraction affected.
resistance. While we observed a general cor-
relation of TGCT cell sensitivity to brentuximab 
vedotin and their CD30 expression levels, ex- 
ceptions exist. The cell line with the second 
highest CD30 expression was amongst the 
least sensitive cell lines to brentuximab vedo-
tin, indicating that the sensitivity to brentux-
imab vedotin is also dependent on other fac-
tors. It has been reported that in a Hodgkin 
lymphoma cell line, the induced brentuximab 
vedotin resistance is caused by increased 
expression of Multidrug resistance protein 1 
(MDR1) which facilitates the export of MMAE 
out of the cells [29]. MDR1 expression has 
been associated with advanced stage TGCTs 
[30], therefore, its expression should be con-
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Figure 10. The efficacy of Brentuximab vedotin in combination with other TGCT chemotherapy drugs in GCT27 cells. Br- 
entuximab vedotin was combined with methotrexate, etoposide, paclitaxel, SN-38 and actinomycin-D for the treat-
ment of GCT27 cells with the cell viability bar chart showing on the top of the combination index plot for each 
treatment. MTX: methotrexate; BV: brentuximab vedotin; Eto: etoposide; Pac: paclitaxel; ActD: actinomycin-D; CI: 
combination index; Fa: Fraction affected.
sidered in the clinical application of brentux-
imab vedotin for TGCT therapy. Other chemo-
therapy drug resistance mechanisms may also 
contribute to brentuximab vedotin resistance, 
which remain to be determined.
Importantly, we have three pairs of parental 
and cisplatin resistant non-seminoma sublines 
[20, 31-33], that allowed the study of brentux-
imab vedotin response in association with the 
treatment and sensitivity to cisplatin, the pri-
mary cytotoxic chemotherapeutic drug for TC- 
GT patient treatment. We found that all the cis-
platin resistant sublines were more resistant to 
brentuximab vedotin treatment and cisplatin 
treatment of CD30 positive TGCT cell lines se- 
lectively killed CD30 positive cells. These data 
indicate that the previously observed reduction 
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in CD30 positive rate in post-chemotherapy 
clinical TGCT samples [11, 15] may be largely 
due to platinum drugs, which are commonly 
included in TGCT treatment. As brentuximab 
vedotin kills not only CD30-expressing cancer 
cells, but also surrounding CD30 negative can-
cer cells through a bystander effect [6-8], this 
raises the question of whether brentuximab 
vedotin should be used before or after plati-
num-based chemotherapy in clinical trials. Br- 
entuximab vedotin had been applied after che-
motherapy in the only two reported small-scale 
clinical studies, with clear but limited benefit. 
Based on our in vitro data and the known low 
toxicity of brentuximab vedotin, we would pro-
pose the application of brentuximab vedotin 
before platinum-based chemotherapy in future 
clinical trials of CD30+ advanced stage TGCTs. 
A pilot phase II trial with brentuximab vedotin 
treatment before any other therapies in Hod- 
|gkin lymphoma showed encouraging results 
[34].
While chemotherapy selectively kills CD30 pos-
itive TGCT cells, leading to reduced CD30 ex- 
pression in the resistant tumor cells and bren-
tuximab vedotin resistance, certain agents su- 
ch as DNA methylation inhibitors, CD30 ligand 
and methotrexate have been reported to induce 
CD30 expression [35-38]. Therefore, a poten-
tial therapeutic option would be to induce CD30 
expression in negative or low-expressing tu- 
mors. It has been reported by Hasanali et al. 
that CD30 expression can be reactivated in 
T-cell prolymphocytic leukemia by demethylat-
ing agent Cladribine and, consequently, induce 
tumor cell sensitivity to brentuximab vedotin 
[35]. However, in contrast with the previous 
observation in leukemia, we found that both 
DNA demethylation agents, Cladribine and 
AZA-C decreased, instead of increasing, CD30 
expression. In the study by Hasanali et al., it 
was shown that Cladribine induced CD30 expr- 
ession in T-cell prolymphocytic leukemias, but 
not in leukemic mantle cell lymphomas [35]. 
CD30 ligand has been shown to upregulate 
CD30 through a positive feedback loop through 
NFKB and IRF4 [36]. Our analysis in two TGCT 
cell lines showed slightly differences in CD30 
expression before and after the treatment but 
in opposite directions. Further investigations 
are required.
Methotrexate has been reported to activate 
CD30 in certain lymphomas [37, 38]. In our 
study of two TGCT cell lines, CD30 expression 
was increased in one cell line and decreased in 
the other after methotrexate treatment, thus, it 
is hard to make conclusion. Our combined tr- 
eatment with brentuximab vedotin and metho-
trexate showed antagonistic effects in both of 
these cell lines as well as another cell line, sug-
gesting that simultaneous treatment with these 
two drugs of TGCT patient should be avoided. 
However, the potential to stimulate CD30 ex- 
pression using methotrexate before brentux-
imab vedotin should be further investigated. 
Interestingly, we found that methotrexate has 
a unique dose-response effect in TGCT cells. At 
a certain dose point, the maximum tumor cell 
killing effect can be achieved by only a slight 
dose increase from the dose where almost no 
effect occurs. Generally, cancer cells within a 
case or cell line are heterogeneous in their sen-
sitivity to a cytotoxic drug and the amount of 
cells killed increases in proportion to drug 
doses. Our TGCT methotrexate dose-response 
curves suggest that there are only two distinct 
populations in each TGCT cell line we tested. 
One population of cells can be killed at certain 
doses of methotrexate and the other popula-
tion of cell can never be killed by methotrexate 
no matter how high the concentration is. This 
not only suggests that TGCT cells provide a 
good model to study methotrexate drug resis-
tance mechanisms, but also indicates the po- 
tential to find a minimum dose for individual 
patients that would minimalize methotrexate 
side effects without sacrificing the maximum 
treatment benefit. 
Most importantly, we investigated the efficacy 
of combinations of brentuximab vedotin with a 
large number of the chemotherapy drugs com-
monly used in the clinic for TGCT treatment. 
Currently, there is limited data on treatment 
efficacy of combined brentuximab vedotin and 
chemotherapeutic drugs commonly used for 
TGCT patient treatments. While certain com-
Table 1. CD30 expression in post-radiothera-
py TGCT samples determined by immunohis-
tochemistry staining
Stain level 0 1+ 2+ 3+
Mixed tumor with EC component 2 12 15 5
NS with EC component 5 8 27 17
EC: embryonal carcinoma; NS: non-seminomous testicu-
lar germ cell tumor. 
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cal trial to investigate the 
clinical efficacy in treating 
advanced TGCTs. Patients 
with any advanced CD30 
positive TGCTs would be 
eligible to receive brentux-
imab vedotin at the cur- 
rent approved dose. In this 
group of patients treatment 
response can be monitored 
with already established tu- 
mor markers. In addition, 
as detected by PET scan-
ning, they are highly gluco- 
se avid and early responses 
can be seen within 21 days 
of the start of therapy. The- 
refore, an initial 3 weeks of 
brentuximab vedotin treat-
ment can be followed by a 
PET scan. If the clinical re- 
sponse was defined as be- 
ing suboptimal on PET sc- 
an, the combined treatm- 
monly used chemotherapy drugs showed an- 
tagonism, we found synergistic/additive effects 
for some drugs, such as etoposide, paclitaxel 
and SN-38. Therefore, combining brentuximab 
vedotin with these non-platinum-based che- 
motherapies may be an effective therapeutic 
approach for patients with advanced stage 
CD30 positive TGCTs. For example, brentux-
imab vedotin may be used together with pacli-
taxel and after 48 hours a platinum drug can be 
added to avoid any direct antagonism.
Surprisingly, we found that all chemotherapy 
drugs in combination with brentuximab vedotin 
showed antagonism in GCT27 cells while half 
of them showed synergistic/additive effects in 
833K and Susa cells, indicating that GCT27 
cells have certain unique features affecting 
their response to brentuximab vedotin. GCT27 
cells are commonly used for TGCT in vitro stud-
ies, including previous studies of brentuximab 
vedotin [8], due to their easy to culture nature. 
Our data suggest that cautions should be ta- 
ken to generalize findings from GCT27 cells for 
brentuximab vedotin studies.
As brentuximab vedotin has been used for the 
treatment of lymphomas with a good safety 
profile, for those drugs where synergy and or 
additive effects were observed, the combined 
treatment will be ready to translate into a clini-
ent with one of the synergistic/additive effect 
chemotherapy drugs revealed from this study 
may be applied. 
Two separate case reports of combination tr- 
eatment by brentuximab vedotin and radiother-
apy of advanced chemotherapy resistant Ho- 
dgkin lymphoma showed good efficacy of the 
combined treatment [39, 40]. In one case, 
complete remission at six months was achiev- 
ed when the case was reported [40]. We deter-
mined the prevalence of CD30 expression in a 
large cohort of post-radiotherapy non-semino-
mous TGCT clinical samples, including mixed 
seminoma and non-seminomous tumors. In > 
90% of cases, CD30 expression remained in 
post-radiotherapy tumor tissues. This indicates 
that brentuximab vedotin will be effective after 
or in combination with radiotherapy. Although 
this combination treatment may not benefit 
many TGCT patients, since radiotherapy is cur-
rently only used in patients with multiple relaps-
es, it might be useful in other CD30 positive 
malignant diseases where radiotherapy is com-
monly used.
In summary, we evaluated the therapeutic effi-
cacy of brentuximab vedotin in correlation with 
CD30 expression in TGCT cell lines. We reveal- 
ed that cisplatin chemotherapy selectively kills 
Figure 11. CD30 immunochemistry staining in TGCT clinical samples. Repre-
sentative images from CD30 negative, weak, medium and strong positive TGCT 
cases were shown.
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CD30 positive TGCT cells, making it a poor 
choice to treat TGCTs after or in combination 
with cisplatin. We also identified combinations 
of brentuximab vedotin with certain chemoth- 
erapy drugs with synergetic or additive effects. 
All these data support the clinical evaluation 
of brentuximab vedotin to treat TGCTs and sh- 
ed light on the optimal combinational therapeu-
tic strategies.
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